The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.

Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.

George Rosenkranz was part of a team in Mexico City that first synthesized norethindrone in 1951.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

A drive for revenue is damaging basic science.

The nasal spray to ease intractable depression appears on the US market after decades without novel antidepressant treatments.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.